A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity

Trial Profile

A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs XmAb 5871 (Primary)
  • Indications Immunological disorders; Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors Xencor
  • Most Recent Events

    • 29 Jun 2017 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
    • 29 Jun 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018.
    • 09 May 2017 According to a Xencor media release, initial data from this trial are expected in late 2018/ early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top